Microvascular Monitoring in Circulatory Shock and Sepsis (MiMICSS)
MiMICSS
1 other identifier
observational
100
1 country
1
Brief Summary
Investigation of the feasibility of using near-infrared spectroscopy (NIRS) to monitor microvascular function in critically ill patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started May 2022
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 27, 2022
CompletedFirst Submitted
Initial submission to the registry
August 2, 2023
CompletedFirst Posted
Study publicly available on registry
August 14, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 31, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
May 31, 2026
CompletedAugust 24, 2025
August 1, 2025
4 years
August 2, 2023
August 19, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Recruitment
Recruitment of two patients per month from each study site
30 days
Secondary Outcomes (3)
protocol adherence
14 days
NIRS and vital sign data quality
14 days
Optimal Map (MAPopt) derivation
14 days
Other Outcomes (2)
ICU mortality
30 days
Hospital mortality
100 days
Study Arms (1)
Observational
All patients
Interventions
NIRS applied on skeletal muscle and brain on days 1, 3, and 8 of ICU admission. Monitoring applied for up to 24hrs on each day.
Eligibility Criteria
Adults admitted to the ICU receiving invasive mechanical ventilation
You may qualify if:
- Admitted to ICU
- Receiving invasive mechanical ventilation
You may not qualify if:
- Body Mass Index \>40
- More than 24 hours has elapsed since ICU admission
- Death is deemed to be imminent and inevitable during the next 24 hours
- Known allergy to the textile components of the device
- Significant clinical jaundice, ecchymosis
- COVID positive microbiological result
- The treating clinician believes that participation in the domain would not be in the best interests of the patient
- Consent declined from patient or authorized third party
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Health Sciences Centre Winnipeg
Winnipeg, Manitoba, R3A 1R9, Canada
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Asher Mendelson, MD, PhD
University of Manitoba
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
August 2, 2023
First Posted
August 14, 2023
Study Start
May 27, 2022
Primary Completion
May 31, 2026
Study Completion
May 31, 2026
Last Updated
August 24, 2025
Record last verified: 2025-08
Data Sharing
- IPD Sharing
- Will not share